Literature DB >> 16990136

The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

Ivaylo I Ivanov1, Brent S McKenzie, Liang Zhou, Carlos E Tadokoro, Alice Lepelley, Juan J Lafaille, Daniel J Cua, Dan R Littman.   

Abstract

IL-17-producing T lymphocytes have been recently shown to comprise a distinct lineage of proinflammatory T helper cells, termed Th17 cells, that are major contributors to autoimmune disease. We show here that the orphan nuclear receptor RORgammat is the key transcription factor that orchestrates the differentiation of this effector cell lineage. RORgammat induces transcription of the genes encoding IL-17 and the related cytokine IL-17F in naïve CD4(+) T helper cells and is required for their expression in response to IL-6 and TGF-beta, the cytokines known to induce IL-17. Th17 cells are constitutively present throughout the intestinal lamina propria, express RORgammat, and are absent in mice deficient for RORgammat or IL-6. Mice with RORgammat-deficient T cells have attenuated autoimmune disease and lack tissue-infiltrating Th17 cells. Together, these studies suggest that RORgammat is a key regulator of immune homeostasis and highlight its potential as a therapeutic target in inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16990136     DOI: 10.1016/j.cell.2006.07.035

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  2000 in total

1.  Topical ROR Inverse Agonists Suppress Inflammation in Mouse Models of Atopic Dermatitis and Acute Irritant Dermatitis.

Authors:  Jun Dai; Min-Kyung Choo; Jin Mo Park; David E Fisher
Journal:  J Invest Dermatol       Date:  2017-07-31       Impact factor: 8.551

Review 2.  Th17 cells in depression.

Authors:  Eléonore Beurel; Jeffrey A Lowell
Journal:  Brain Behav Immun       Date:  2017-08-03       Impact factor: 7.217

3.  An antigen-specific semi-therapeutic treatment with local delivery of tolerogenic factors through a dual-sized microparticle system blocks experimental autoimmune encephalomyelitis.

Authors:  Jonathan J Cho; Joshua M Stewart; Theodore T Drashansky; Maigan A Brusko; Ashley N Zuniga; Kyle J Lorentsen; Benjamin G Keselowsky; Dorina Avram
Journal:  Biomaterials       Date:  2017-07-24       Impact factor: 12.479

Review 4.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

5.  Identification of a Signaling Mechanism by Which the Microbiome Regulates Th17 Cell-Mediated Depressive-Like Behaviors in Mice.

Authors:  Eva M Medina-Rodriguez; Derik Madorma; Gregory O'Connor; Brittany L Mason; Dongmei Han; Sapna K Deo; Mark Oppenheimer; Charles B Nemeroff; Madhukar H Trivedi; Sylvia Daunert; Eléonore Beurel
Journal:  Am J Psychiatry       Date:  2020-07-31       Impact factor: 18.112

Review 6.  IL-17+ γδ T cells as kick-starters of inflammation.

Authors:  Pedro H Papotto; Julie C Ribot; Bruno Silva-Santos
Journal:  Nat Immunol       Date:  2017-05-18       Impact factor: 25.606

7.  IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice.

Authors:  Timothy B Oriss; Mahesh Raundhal; Christina Morse; Rachael E Huff; Sudipta Das; Rachel Hannum; Marc C Gauthier; Kathryn L Scholl; Krishnendu Chakraborty; Seyed M Nouraie; Sally E Wenzel; Prabir Ray; Anuradha Ray
Journal:  JCI Insight       Date:  2017-05-18

Review 8.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 9.  A tale of two cytokines: IL-17 and IL-22 in asthma and infection.

Authors:  Michelle L Manni; Keven M Robinson; John F Alcorn
Journal:  Expert Rev Respir Med       Date:  2013-12-10       Impact factor: 3.772

Review 10.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.